AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05334030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Swing Resistance
Description: On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting
Study NCT05334030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Max Trajectory Control
Description: On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - Bilateral;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting
Study NCT05361863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic brackets
Description: Interventions involving orthodontic brackets of different slot sizes
Study NCT05361863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic brackets
Description: Interventions involving orthodontic brackets of different slot sizes
Study NCT05236257 — intervention group
Intervention type: DRUG
Intervention: Larotrectinib (Vitrakvi, BAY2757556)
Description: Pediatric patients with IFS harboring an NTRK gene fusion.
Study NCT05236257 — intervention group
Intervention type: DRUG
Intervention: Standard of Care
Description: Standard of care for the patients from the eligible external cohorts.
Study NCT04945291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile applications
Description: the participant will use a mobile application to log their calories
Study NCT05296239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SimpleC Wellness Platform with Social Robot Interaction
Description: Once respondents enroll, they will receive the SimpleC Wellness Platform, including introduction training on the SAR system. During the study period, participants and others will receive instructions for the SAR system and use it as part of scheduled interactions, which includes interactions as part of the general schedule. In the third week, the social robot will be installed, and staff trained in group sessions as available. Participants may use the full SAR system as they are willing.~Interactions specific to the virtual and physical robot include notifications to join activities as per community schedule as well as trivia.
Study NCT06447870 — intervention group
Intervention type: DRUG
Intervention: biologic therapy(eg:IFX,ADA,UST,VDZ)
Description: The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
Study NCT06379854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy
Study NCT06379854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk rotation exercises,deep diaphragmatic also chest physiotherapy
Description: Postural Drainage Frequency: 3 sessions/week Intensity: 5 to 10 minutes Time: For 4 weeks Type: chest physiotherapy~Percussion F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Vibration F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Shaking F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Huffing and coughing F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy~Deep Diaphragmatic Breathing Exercise F: 3 sessions/week I: 3 to 5 minutes T: For 4 weeks T: chest physiotherapy TLFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises TFROM F: 3 sessions/week I: 5 to 10 minutes T: For 4 weeks T: Mobilization Exercises
Study NCT06522763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.
Description: The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
Study NCT06522763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ
Description: The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.
Study NCT06515886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Examination
Description: Clinical examination of a dental implant
Study NCT06515886 — intervention group
Intervention type: PROCEDURE
Intervention: Peri-implant crevicular fluid
Description: Collection of a sample of peri-implant crevicular fluid
Study NCT05502809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep-frozen platelets
Description: Cryopreserved platelets
Study NCT05502809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deep-frozen platelets
Description: Cryopreserved platelets
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on low body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on middle body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on high body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on low body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on middle body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on high body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on low body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on middle body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on high body surface area
Description: Part A: Single topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose A on high body surface area twice daily
Description: Part B: Multiple topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YR001 Dose B on high body surface area twice daily
Description: Part B: Multiple topical dose
Study NCT05718921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on high body surface area twice daily
Description: Part B: Multiple topical dose
Study NCT05056311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid Website
Description: The (private) decision aid website contains information in text, graphic, and video form about hypospadias and considerations for choosing surgery and no surgery.
Study NCT05392543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brunnstrom movement therapy.
Description: Group A: Will be treated with Brunnstrom movement therapy for three days in a week for four weeks (1 h) approximately 12 sessions to every subject.~Subjects received Brunnstrom hand manipulation (BHM) and conventional occupational therapy for the upper extremity and lower extremities. The detailed BHM is applied on hand. The major goal of the BHM was the acquisition of mass grasp and mass release of objects. Once the goal was achieved, more prehensile activities were focused. Reflexive, passive, synergistic and active movements were used sequentially to enhance the hand recovery.
Study NCT05392543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Group B: Will be treated with Mirror therapy 45 minutes, for three days in a week for four weeks approximately 12 sessions to every subjects.~First 30 minutes therapy consists of conventional therapy as given conventional tasks only with the affected upper extremity. 15 minutes were continued with mirror. Mirror is placed in front of the midline of the patient so that the affected limb is fully covered by the mirror and the reflection of the unaffected limb is fully visible. The affected limb positioned in a safe and comfortable position behind the mirror. The non-affected limb should be positioned in a similar position as the affected limb, as this facilitates the intensity of the mirror illusion. Patients in the experimental group received 45 minutes of consecutive session.
Study NCT06055452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
Study NCT06055452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant in the placebo group takes matching placebo.
Study NCT06297642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 injection
Description: Anti-CD47 monoclonal antibody
Study NCT06297642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)
Study NCT04983927 — intervention group
Intervention type: DEVICE
Intervention: cASPECTS
Description: Clinical decision support system for scoring ASPECTS score
Study NCT04956068 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: A novel drug delivery system using the CapnoPen device which allows the aerolisation of chemotherapeutic agents within the peritoneal cavity. PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.
Study NCT05056363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Traditional Scoliosis Exercises
Description: Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
Study NCT05056363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Traditional Scoliosis Exercises
Description: Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
Study NCT05056363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Training
Description: Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
Study NCT05470530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone was given either intrathecal or intravenous in spinal anesthesia during ceaseran section while normal saline was given in control group
Study NCT05589129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Supplement
Description: Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
Study NCT05589129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Placebo Control
Description: Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
Study NCT06393504 — intervention group
Intervention type: DRUG
Intervention: Daridorexant
Description: Daridorexant received during or shortly prior to pregnancy.
Study NCT06393504 — intervention group
Intervention type: DRUG
Intervention: Non-orexin receptor antagonist insomnia medication
Description: Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
Study NCT06393504 — intervention group
Intervention type: OTHER
Intervention: No insomnia medication
Description: No insomnia medication received during or shortly prior to pregnancy.
Study NCT05989386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Description: During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
Study NCT05989386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine Swab
Description: No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
Study NCT04998825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proteoglycan F
Description: Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
Study NCT04998825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
Study NCT05235815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retro SCTL compartment block
Description: For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4).
Study NCT06727123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: Motivational interviews will be conducted with diabetic patients for 6 months. Patients will be trained before starting the interviews.
Study NCT06727123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No application will be made. Routine follow-ups will be made.
Study NCT05828277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repotrectinib (TPX-0005)
Description: Oral repotrectinib (TPX-0005)
Study NCT06441734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cbc serum ferritin serum iron
Description: by using sample of blood to do cbc and serum ferritin and serum iron during 1year
Study NCT06391866 — intervention group
Intervention type: OTHER
Intervention: extracorporeal circulation
Description: extracorporeal circulation during cardiosurgical operation
Study NCT05026216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qwo
Description: Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenases AUX-I and AUX-II, in an approximate 1:1 mass ratio, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria. Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids. Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids.
Study NCT05755672 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Neo-adjuvant and adjuvant chemotherapy with curative intent, according to the current clinical practice guidelines
Study NCT05755672 — intervention group
Intervention type: PROCEDURE
Intervention: Resection of the primary tumor
Description: Surgical resection of the primary tumour, according to the current clinical practice guidelines
Study NCT05755672 — intervention group
Intervention type: PROCEDURE
Intervention: Resection of tumour metastases
Description: Surgical resection of tumour metastases, according to the current clinical practice guidelines
Study NCT05755672 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling during chemotherapy
Description: Drawing of blood samples several times during patient visits for chemotherapy regimen
Study NCT06433089 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block was performed before surgery
Study NCT05681494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: after access cavity preparation, the working length will be determined. chemo-mechanical preparation will be done, and teeth will be obturated. final restoration will be placed.
Study NCT05681494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital pulp therapy
Description: exposed pulp will be capped with 3 mm calcium silicate material
Study NCT05630677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 solution for infusion
Description: Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
Study NCT05630677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 oral suspension
Description: Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
Study NCT05630677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 film-coated tablet
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
Study NCT05630677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055 film-coated tablet
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
Study NCT05630677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, Delayed-release tablet
Description: Subjects will receive oral doses of rabeprazole twice daily 3 days prior to AZD5055 single dose and 4 days after the AZD5055 single dose including the day that AZD5055 is dosed under fasted conditions \[Study Day 10 to 18\].
Study NCT05630677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, Delayed-release tablet
Description: Subjects will receive oral doses of rabeprazole twice daily prior to AZD5055 single dose under fed conditions (low-fat standard breakfast) and then continued for 2 days.
Study NCT06393166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection
Description: Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle Gemcitabine hydrochloride: 1g/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle 5-FU: 2400 mg/m2 ,ivgtt over 46h, D29-30, every 6 weeks for a treatment cycle Oxaliplatin: 85 mg/m2 ,ivgtt, D29, every 6 weeks for a treatment cycle LV: 400 mg/m2 ,ivgtt over 2h, D29, every 6 weeks for a treatment cycle Serplulimab Injection: 3mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle. Bevacizumab Injection: 5mg/kg,ivgtt,D1, every 2 weeks for a treatment cycle.
Study NCT05266677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blend of glycerides at certain proportions
Description: combination of glycerides in specific proportions in a liquid oral supplement
Study NCT05266677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: glycerides used in current formulas
Description: glycerides used in current formulas in a liquid oral supplement
Study NCT05156346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAVES
Description: LEAVES consists of 10 modules of readings and exercises. Readings are filled with evidence-based information on grief-related topics (e.g., how to positively influence thoughts, emotions and behaviours), followed by exercises which encourage mourners to actively reflect on what was learned and apply their new knowledge into their grief journey and coping strategies (e.g., how to change attentional focus). Users are encouraged to work through one module per week and complete the assignments.